- $148.58m
- $194.70m
- $149.16m
Neuronetics Inc reports results for the quarter ended in December - Earnings Summary
U.S. STOCKS ON THE MOVE-Nasdaq, Albemarle, Haemonetics
U.S. STOCKS ON THE MOVE-AeroVironment, Tesla, GitLab
Medtech co Neuronetics rises on upbeat Q4 results
Neuronetics Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Neuronetics Reports Prelim Q4 And Fiscal Year 2023 Results
Brief: NeuroStar TMS Receives Expanded Regulatory Approval In Japan
Brief: Neuronetics - Cash And Cash Equivalents Were $35.8 Million As Of Sept. 30, 2023
Neuronetics Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Neuronetics Draws Down Remaining $22.5 Million Available Under Credit Facility
Brief: J. Carlo Cannell Reports 9.80% Passive Stake In Neuronetics As Of Sept 5
Neuronetics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Neuronetics Reports Record Second Quarter 2023 Financial And Operating Results
Brief: Neuronetics Q2 Operating Expenses USD 20.1 Mln
Neuronetics Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: Neuronetics Announces Expanded TMS Therapy Access Through Aetna Health Plans
Brief: Neuronetics Receives 510(K) Clearance For Neurostar Advanced Therapy
Neuronetics rises on robust Q1 results, revenue forecast
Neuronetics Inc reports results for the quarter ended in March - Earnings Summary